Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $207.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price raised by Wells Fargo & Company from $161.00 to $207.00 in a report released on Tuesday morning, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a buy rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. StockNews.com raised shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, April 29th. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an equal weight rating in a research note on Tuesday. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a buy rating in a research note on Monday. Finally, BMO Capital Markets reissued an outperform rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. Eight research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $245.14.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $247.00 on Tuesday. The stock has a market cap of $31.24 billion, a P/E ratio of -92.16 and a beta of 0.30. The firm has a 50 day moving average price of $157.89 and a 200 day moving average price of $164.23. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same period in the previous year, the firm posted ($1.40) EPS. The business’s quarterly revenue was up 54.8% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,357 shares of company stock worth $13,436,711. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Quent Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $38,000. Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at about $30,000. Finally, GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $52,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.